Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 15, 2023 | June 20, 2023 |
| Alkermes plc.ALKS · Entity 2392 | Director | June 14, 2022 | June 16, 2022 |
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | CMO & Pres, Global Marketing | May 22, 2006 | May 24, 2006 |
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | March 15, 2024 | April 04, 2024 |
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 19, 2019 | June 21, 2019 |
| INCYTE CORPINCY · Entity 3182 | Director | March 31, 2022 | April 04, 2022 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 10, 2022 | June 14, 2022 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 04, 2020 | June 05, 2020 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | May 29, 2025 | May 31, 2025 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | November 11, 2021 | November 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,121 |
Reported balance
After 2023-06-15 transaction · row 1
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 4,121 · Balance 9,121 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2033-06-14 | Direct | 12,787 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Grant · Acquired 12,787 · Balance 12,787 F2: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.
F2: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.
Alkermes plc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 53,124 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Exercise / conversion · Acquired 7,585 · Balance 53,124 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Exercise / conversion · Disposed 7,585 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: This award is fully vested in accordance with its terms.
BRISTOL MYERS SQUIBB CO
Report date May 22, 2006 · Filed May 24, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 87,003 |
Reported balance
After 2006-05-22 transaction · row 1
1 source rowRow 1 · 2006-05-22 · Tax withholding · Disposed 3,396 · Balance 87,003 F1: Shares withheld for payment of taxes upon vesting of restricted stock. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,543.43 |
Reported balance
Holding disclosure · report date 2006-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,543.43 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for payment of taxes upon vesting of restricted stock.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
Black Diamond Therapeutics, Inc.
Report date March 15, 2024 · Filed April 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,054 |
Reported balance
After 2024-03-15 transaction · row 1
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 3,253 · Balance 38,054 F1: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024.
Carisma Therapeutics Inc.
Report date June 19, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2029-06-18 | Direct | 105,000 |
Reported balance
After 2019-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-19 · Grant · Acquired 105,000 · Balance 105,000 F1: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
INCYTE CORP
Report date March 31, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,768 |
Reported balance
After 2022-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 249 · Balance 17,768 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
F2: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 10, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 51,204 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 51,204 · Balance 51,204 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Voyager Therapeutics, Inc.
Report date June 04, 2020 · Filed June 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.79 · Expires 2030-06-04 | Direct | 15,000 |
Reported balance
After 2020-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-04 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.
ZEVRA THERAPEUTICS, INC.
Report date May 29, 2025 · Filed May 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.62 · Expires 2035-05-28 | Direct | 30,000 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
bluebird bio, Inc.
Report date November 11, 2021 · Filed November 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,894 |
Reported balance
After 2021-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-11 · Other · Acquired 6,241 · Balance 11,894 F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.07 · Expires 2023-04-29 | Direct | 25,953 |
Reported balance
After 2021-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-11 · Other · Disposed 26,361 · Balance 25,953 F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on April 29, 2013 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.54 · Expires 2024-06-11 | Direct | 7,384 |
Reported balance
After 2021-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-11 · Other · Disposed 7,500 · Balance 7,384 F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 11, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.14 · Expires 2025-06-04 | Direct | 7,384 |
Reported balance
After 2021-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-11 · Other · Disposed 7,500 · Balance 7,384 F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 4, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2026-06-02 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F7: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 2, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.29 · Expires 2027-06-08 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F8: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.20 · Expires 2028-06-20 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F9: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.78 · Expires 2029-06-06 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F10: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.93 · Expires 2030-06-18 | Direct | 2,953 |
Reported balance
After 2021-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-11 · Other · Disposed 3,000 · Balance 2,953 F11: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2031-06-15 | Direct | 10,038 |
Reported balance
After 2021-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-11 · Other · Disposed 5,000 · Balance 10,038 F12: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.
F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.
F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on April 29, 2013 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 11, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 4, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F7: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 2, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F8: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F9: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F10: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F11: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F12: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2021 Filed May 28, 2021 11:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,010 | $0.00 Strike: $83.16 | $0.00 |
DisclosureSEC source: 0001209191-21-036403 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 26, 2021 Filed May 28, 2021 11:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036403 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,801 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017786 · form4.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This restricted stock unit award vested in full on 5/20/2021. F1 · derivative.expiration_date: This restricted stock unit award vested in full on 5/20/2021. Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:34 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,404 | $21.92 | $30,775.68 |
DisclosureSEC source: 0001127602-21-017786 · form4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,300 Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017786 · form4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 19:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.60 | $0.00 |
DisclosureSEC source: 0001127602-21-014126 · form4.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2021-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 19:22 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 25,000 | $20.00 | $500,120.00 |
DisclosureSEC source: 0001127602-21-014126 · form4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,600 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 19:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 25,000 | $14.60 | $365,000.00 |
DisclosureSEC source: 0001127602-21-014126 · form4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 21:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 225 | $81.27 | $18,285.75 |
DisclosureSEC source: 0001209191-21-024154 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,878 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001127602-21-001770 · form4.xml · derivative · entry 4 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires 2021-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001127602-21-001770 · form4.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2021-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 20,000 | $12.62 | $252,400.00 |
DisclosureSEC source: 0001127602-21-001770 · form4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 15,000 | $12.62 | $189,300.00 |
DisclosureSEC source: 0001127602-21-001770 · form4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 213 | $86.98 | $18,526.74 |
DisclosureSEC source: 0001209191-21-001195 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,653 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:32 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,578 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030574 · form4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,578 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:32 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,509 | $0.00 Strike: $18.82 | $0.00 |
DisclosureSEC source: 0001127602-20-030574 · form4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,509 Underlying: Ordinary Shares · 11,509 shares Expires 2030-12-02 F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 197 | $89.74 | $17,678.78 |
DisclosureSEC source: 0001209191-20-052633 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,440 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:26 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.97 | $0.00 |
DisclosureSEC source: 0001209191-20-048766 · doc4.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning May 20, 2011, options become exercisable in full on May 20, 2012. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:26 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 20,000 | $94.51 | $1,890,200.00 |
DisclosureSEC source: 0001209191-20-048766 · doc4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,243 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $94.50 - $94.58. F3 · balance_after: This includes an 1,282 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:26 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 20,000 | $18.97 | $379,400.00 |
DisclosureSEC source: 0001209191-20-048766 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:57 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 182 | $103.97 | $18,922.54 |
DisclosureSEC source: 0001209191-20-039784 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,243 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 18:06 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $31.95 | $0.00 |
DisclosureSEC source: 0001209191-20-039888 · doc4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-06-28 F1 · derivative.exercise_date: This option award was granted on June 29, 2020. The shares underlying the award shall vest in equal monthly installments through June 29, 2023. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 16:27 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $64.09 | $0.00 |
DisclosureSEC source: 0001562180-20-004618 · primarydocument.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2030-06-18 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 16:27 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004618 · primarydocument.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,653 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 16:27 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004618 · primarydocument.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.79 | $0.00 |
DisclosureSEC source: 0001104659-20-070326 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,514 | $0.00 Strike: $98.68 | $0.00 |
DisclosureSEC source: 0001209191-20-032583 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032583 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,061 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017767 · form4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,823 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001127602-20-017767 · form4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,823 Underlying: Ordinary Shares · 12,823 shares Expires 2030-05-20 F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 243 | $73.23 | $17,794.89 |
DisclosureSEC source: 0001209191-20-022684 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,779 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 196 | $87.32 | $17,114.72 |
DisclosureSEC source: 0001209191-20-000850 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 18,334 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · derivative · entry 12 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,334 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Beginning May 21, 2010, options become exercisable in full on May 21, 2011. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 22,884 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · derivative · entry 11 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,884 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning May 21, 2010, options become exercisable in 37 installments, with the first 25.00% vesting on May 21, 2011 and the remainder vesting monthly over three years. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 18,334 | $83.87 | $1,537,672.58 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 8 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $83.12 - $84.21. F5 · balance_after: This includes an 1,520 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 18,334 | $12.46 | $228,441.64 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 7 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 22,884 | $83.87 | $1,919,281.08 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 6 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $83.12 - $84.21. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 22,884 | $12.46 | $285,134.64 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 5 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 1,540 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · derivative · entry 10 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,884 Underlying: Common Stock · 1,540 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning May 21, 2010, options become exercisable in 37 installments, with the first 25.00% vesting on May 21, 2011 and the remainder vesting monthly over three years. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,540 | $83.60 | $128,744.00 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 4 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $83.50 - $83.70. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,540 | $12.46 | $19,188.40 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 10,576 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · derivative · entry 9 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,424 Underlying: Common Stock · 10,576 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning May 21, 2010, options become exercisable in 37 installments, with the first 25.00% vesting on May 21, 2011 and the remainder vesting monthly over three years. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,576 | $84.16 | $890,076.16 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $84.10 - $84.30. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 10,576 | $12.46 | $131,776.96 |
DisclosureSEC source: 0001209191-19-055857 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 225 | $74.23 | $16,701.75 |
DisclosureSEC source: 0001209191-19-051639 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:33 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 208 | $84.96 | $17,671.68 |
DisclosureSEC source: 0001209191-19-040315 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,115 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:15 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-19-000042 · wf-form4_156114810117022.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 22:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $24.68 | $0.00 |
DisclosureSEC source: 0001104659-19-035995 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:22 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $122.01 | $0.00 |
DisclosureSEC source: 0001209191-19-035789 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2029-06-06 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 6, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:22 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035789 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 6, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.